ISPOR 2024 | May 5-8, 2024 , Atlanta, GA |
ISPOR 2024 | May 5-8, 2024 , Atlanta, GA |
Sunday May 5, 2024
ISPOR North America HTA Roundtable. Presenter: Scott Ramsey (Invitation Only).
12:00 PM - 5:00 PM
Curta Welcome Reception (Invitation Only).
5:30 PM - 7:30 PM
Monday May 6, 2024
Poster Session 1: A Targeted Literature Review to Identify the Dimensions of Sustainable Global Biosimilars Markets. Presenter: Tory Dayer.
10:30 AM - 1:30 PM
Spotlight Session S1: Medicare Drug Price Negotiation: Lessons from the First 10 Drugs Selected. Moderated by Sean Sullivan.
1:45 PM - 2:45 PM
Poster Session 2: Budget Impact Analysis of Zanubrutinib + Obinutuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma in the United States. Presenter: Kristen Migliaccio-Walle.
3:30 PM - 6:30 PM
Poster Session 2: Impact of Slowing Alzheimer’s Disease (AD) Progression: A Simulation Model in a Population of Patients with Early AD in the United States. Presenter: Lisa Bloudek.
Friends of Curta Roving Party (Swing by Booth 531 to Get the Invite)
8:00 PM - 12:00 AM
Tuesday May 7, 2024
Poster Session 3: Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective. Presenter: Cynthia Gong.
10:30 AM - 1:30 PM
Poster Session 4: Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the U.S.: An Updated Analysis. Presenter: David Campbell.
3:30 PM - 6:30 PM
Poster Session 4: Understanding the Disconnect: Characterizing Trends in Inclusion of Family and Informal Caregiver Spillover in US Value Assessments. Presenter: Rajshree Pandey.
Wednesday May 8, 2024
Poster Session 5: Adherence and Persistence of Oral Anticoagulants for Treatment of Atrial Fibrillation across Stroke and Bleeding Risk Strata. Presenter: Lizzy Brouwer.
9:00 AM - 11:00 AM
Breakout Session 8: Addressing Key Challenges in the Setting of Tumor-Agnostic Drugs: Meeting an Unmet Need? Discussant: Yilin Chen.
10:00 AM - 11:00 AM
Publications
RECENT PRESENTATIONS AND PUBLICATIONS
Systematic Literature Review and Meta-Analysis of HER2 Amplification, Overexpression, and Positivity in Colorectal Cancer. JNCI Cancer Spectr. 2024 Jan 4;8(1):pkad082.
Cost-effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States. Value Health. 2023 Dec 1:S1098-3015(23)06194-6.
Estimated Impact of ECHELON-1 Overall Survival on Productivity Costs in Stage III/IV Classical Hodgkin Lymphoma in the United States. J Manag Care Spec Pharm. 2023 Nov 3:1-9.
Has the Centers for Medicare & Medicaid Services Implicitly Adopted a Value Framework for Medicare Drug Price Negotiations? Value Health. 2023 Oct 21:S1098-3015(23)06150-8.
Designing a Value-Based Formulary for a Commercial Health Plan: A Simulated Case Study of Diabetes Medications. Value Health. 2023 Jul;26(7):1022-1031.
Recommendations for Economic Evaluations of Cell and Gene Therapies: A Systematic Literature Review with Critical Appraisal. Expert Rev Pharmacoecon Outcomes Res. 2023 Jun;23(5):483-497.
Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling. Clinical Epidemiology. 2023 Jun 21;15:765-773.
Health Care Costs and Resource Use of Managing Hemophilia A: A Targeted Literature Review. J Manag Care Spec Pharm. 2023 Jun;29(6):647-658.
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator. Oncologist. 2023 May 8;28(5):e242-e253.
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC). Curr Oncol. 2023 Mar 26;30(4):3637-3647.
Alternatives To The QALY For Comparative Effectiveness Research. Health Affairs Forefront. April 21, 2023.
Total Healthcare Cost Savings Through Improved Bipolar I Disorder Identification Using the Rapid Mood Screener in Patients Diagnosed with Major Depressive Disorder. Curr Med Res Opin. 2023 Apr;39(4):605-611.
